Bibliographical noteFunding Information:
N. W. has received research grants and conference support from most major pharmaceutical companies; none represents a conflict of interest with the content of this article. D. M. L. has received grants, speaking invitations and conference invitations from most major pharmaceutical companies and holds shares in GSK, Pfizer, AstraZeneca, Merck, Dechra and Eco Animal Health within diversified portfolios. S. M. has received conference support from numerous pharmaceutical companies. J. H. has received a travel grant funded by Wyeth pharmaceuticals, ESCMID and ISC to attend a conference. All other others—nothing to declare.
- Emerging infections
- Glycylcycline resistance